Johnson & Johnson has announced its financial results for Q2 2019.
According to the company, net sales during the second quarter of 2019 reached $20.56 billion, a 1.3% decrease from $20.83 billion during Q2 2018.
Consumer sales grew by 2.3% driven by Neutrogena, Aveeno and OGX beauty products as well as international Listerine mouthwash in oral care products and U.S. baby care products.
Alex Gorsky, chairman and CEO, and, "We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses. Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions. I am proud of our talented colleagues across Johnson & Johnson who continue to deliver significant healthcare advances to improve the lives of patients and consumers around the world."